- Commissioner Makary and Center Directors Tidmarsh and Prasad Announce 2 New Programs for Ultra-Rare Disease Therapies: RDEP and Bespoke September 8, 2025
- Radical Transparency, Act II: FDA Releases 89 Previously Unpublished Complete Response Letters September 5, 2025
- Cannabis Redux: Marijuana Rescheduling Act Reintroduced in the U.S. House September 3, 2025
- FDA Lends a Single Arm: Papzimeos Approval Highlights FDA’s Willingness to Rely on Single-Arm Trials for Rare Diseases September 2, 2025
- Silicon Valley Life Sciences Day August 29, 2025
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized
Sell-Out Crowd for HPM’s Enforcement Webinar
April 29, 2025We have reached maximum capacity for this Thursday’s webinar! We are excited by the large interest in this topic, and are eager to share our insights about the latest changes impacting the FDA-regulated industry. Registration is closed, but if you would like to be put on a waitlist or receive a recording of the webinar, please contact Amy Vasvary (avasvary@hpm.com). If your plans have changed and you can no longer attend, please contact Amy so we can open your space to the waitlist.
Categories: Enforcement
Search FDA Law Blog
Subscribe
Latest Tweets
Tweets by @fdalawblogAwards & Honors
- Best Lawyers in America® – 2025
- Ranked in Chambers USA – 2024
- Commissioner Makary and Center Directors Tidmarsh and Prasad Announce 2 New Programs for Ultra-Rare Disease Therapies: RDEP and Bespoke September 8, 2025
- Radical Transparency, Act II: FDA Releases 89 Previously Unpublished Complete Response Letters September 5, 2025
- Cannabis Redux: Marijuana Rescheduling Act Reintroduced in the U.S. House September 3, 2025
- FDA Lends a Single Arm: Papzimeos Approval Highlights FDA’s Willingness to Rely on Single-Arm Trials for Rare Diseases September 2, 2025
- Silicon Valley Life Sciences Day August 29, 2025
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized